Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

Patients with chronic lymphocytic leukemia show higher risks for skin cancer, as well as skin cancer-specific metastasis and ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

CLL is linked to higher skin cancer risk and worse outcomes. Learn more about this large cohort study and its clinical ...

Pharmac estimates the new approach will save approximately 3,700 infusion hours annually, easing pressure on oncology ...

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys-CLL is one ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have ...

Consuming high levels of the sugar substitute sucralose was linked with a worse response to immunotherapy and poorer survival in patients with melanoma and lung cancer. (Cancer Discovery) The FDA ...

Serious infections occurred in 45.6% of patients and increased monthly hospital costs by AU$22,905, with elevated expenditure persisting for six months after the index infection. Episode-level excess ...